AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 38 Publications

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435

Genome Biol, 2016, 17(1):149

PubMed: 27380875

Nat Commun, 2014, 5:3384

PubMed: 24594970

Autophagy, 2012, 9(1):74-92

PubMed: 23196898

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460
Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584

Mol Oncol, 2013, 33:404-18

PubMed: 24444656

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969

Clin Sci, 2015, 128(8):517-26

PubMed:

Mol Cancer Res, 2015, 13(2):223-30

PubMed:

Mol Cancer Res, 2015, 13(1):120-9

PubMed:

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948
J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218

Am J Cancer Res, 2014, 4(6):824-837

PubMed:

Biochem J, 2015, 465(2):227-38

PubMed: 25353634

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602

J Chromatogr A, 2015, 1388:267-73

PubMed:

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484

PLoS One, 2013, 8(2):e56567

PubMed: 23451056

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667
Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798

8 Customer Reviews

PC3-LN4 cells were treated with GSK690693 (5 uM) alone, or in combination with PP242 (2 uM) or AZD8055 (1 uM) for 24 h, and immunoblotting performed.

Cancer Res 2013 73(11), 3402-11. AZD8055 purchased from Selleck.

mTOR kinase inhibitor AZD8055 activates PI3K accompanied with induction of expression of EGFR, HER2, HER3 and IRS1. Serum-deprived CHO-EGFP-AKT cells were incubated with 50 nM AZD8055 for 24 hr. The EGFP signal was detected using confocal microscopy. The white arrows indicate EGFP-AKT located on cellular membrane.

Int J Cancer 2014 135(10), 2462-74. AZD8055 purchased from Selleck.
HUVEC were treated with either RAD001 or AZD8055 before PA treatment. p53, GPX1, p53 acetylation, and subcellular PTEN were analyzed with corresponding antibodies. The blot is a representative of the results of three experiments. Values (mean盨D) are expressed as fold over untreated control. *p<0.05 versus their corresponding control groups in the one-way ANOVA.

Antioxid Redox Signal 2014 20(9), 1382-95. AZD8055 purchased from Selleck.

CSCs^+24/44/ESA at 5,000 cells per well with stem cell culture media in triplicate in an ultra-low adhesion plate were treated with 5 umol/L BMS-777607, 1 umol/L AZD8055 alone, or in their different combinations. Cells were cultured for 72 hours. Cell viability was determined by the MTS assay. Percentages of polyploid cells were determined by counting 300 cells from two different regions. Results shown here were from one of two experiments with similar results.

Mol Cancer Ther 2014 13(1), 37-48. AZD8055 purchased from Selleck.
mTOR, P70S6K1, 4E-BP1 and PCNA activation in the basilar artery of SAH. Top, Western blotting bands of antibodies, bottom, density of the protein band from each group. A, mTOR activation in the basilar artery demonstrated an elevated expression of mTOR on day 7 following SAH in SAH and SAH+DMSO animals. The mTOR inhibitors, Rapamycin and AZD8055 reduced the enhanced expression of mTOR (pb0.05, ANOVA). B. P70S6K1 activation. C. 4E-BP1 activation. D. PCNA activation. Rapamycin and AZD8055 significantly decreased the expression of P70S6K1, 4E-BP1 and PCNA compared with the SAH and SAH+DMSO (pb0.05, respectively; ANOVA). There was no significant difference between the two inhibitors in mTOR, P70S6K1, 4E-BP1 and PCNA expression.

Exp Neurol 2012 233, 799-806. AZD8055 purchased from Selleck.

Induction of TCTP expression through 5-FU or oxaliplatin is inhibited by mTOR kinase inhibitors. HCT116 cells were treated for 48 h with 5-FU or oxaliplatin at the indicated concentrations. Where indicated, AZD 8055 (100 nM) or PP242 (1 μM) were added. TCTP levels were assessed by western blotting; signals were quantified and normalised against α-tubulin as a loading control. As a readout of mTOR activity, phosphorylation of the ribosomal protein S6 at Ser 240/244 was assessed using a phospho-specific antibody. a. Representative western blots demonstrating the alteration of the levels of TCTP protein and of phospho-ribosomal protein S6, respectively, in relation to the drug concentration.

Cell Commun Signal, 2017, 15(1):9. AZD8055 purchased from Selleck.
(A) HCT116 or MDA-MB-468 cells were treated with 500 nM AZD8055 for the indicated times. Cell lysates were immunoblotted with the indicated antibodies. (B) HCT116 or MDA-MB-468 cells were treated with 50 nM rapamycin. 500 nM AZD8055, 1 uM MK2206 or dimethyl sulfoxide (DMSO) as control for 12 h. Cell lysates were immunoblotted with the indicated antibodies.

Oncotarget 2014 5(15), 6015-27. AZD8055 purchased from Selleck.

After starved in serum-free medium for 24h , A549 cells incubated with the indicated concentrations of AZD8055 for 3h , followed by 20-minute stimolation of 100ng/ml EGF

Dr. Zhang of Tianjin Medical University. AZD8055 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	M4jmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmH0TWM2OD1yLkCyN\|MyKM7:TR?=	NE\NdolUSU6JRWK=
NCI-H720	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHITWM2OD1yLkCyPVM5KM7:TR?=	M1raV3NCVkeHUh?=
KARPAS-45	NFfDc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMEOzO\|Eh\|ryP	NGHLcXBUSU6JRWK=
EW-3	MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjJcYlKSzVyPUCuNFQxPTZizszN	M3\GZXNCVkeHUh?=
SBC-1	M{jvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq5XnUxUUN3ME2wMlA1PThzIN88US=>	MnfrV2FPT0WU
NCI-H209	NFe0U\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:3TWM2OD1yLkC1OFU{KM7:TR?=	M{X1NHNCVkeHUh?=
EoL-1-cell	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmS4TWM2OD1yLkC2OVY6KM7:TR?=	MX;TRW5ITVJ?
H9	NEnK[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1:0fWlEPTB;MD6wOlY6OiEQvF2=	NIrZfpBUSU6JRWK=
AN3-CA	NHPiWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[3eG1jUUN3ME2wMlA4QTVzIN88US=>	M4K3R3NCVkeHUh?=
HH	NGnoWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrjTWM2OD1yLkC4NFA6KM7:TR?=	MXrTRW5ITVJ?
KU812	NV;wbIdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLiTWM2OD1yLkC4NFQ{KM7:TR?=	MoO3V2FPT0WU
DU-4475	NXj0TVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGO3NJZKSzVyPUCuNFgxPDdizszN	NInob3FUSU6JRWK=
CTV-1	NHfReJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwMEi2OFEh\|ryP	NFTt[ZBUSU6JRWK=
BV-173	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LsVmlEPTB;MD6wPVA3OSEQvF2=	NYDaflZxW0GQR1XS
ES5	M1[yS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HTRmlEPTB;MD6wPVM2KM7:TR?=	NUHxVXkyW0GQR1XS
G-402	NWLJT\|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TaTGlEPTB;MD6wPVk5KM7:TR?=	NVu0OGRqW0GQR1XS
MV-4-11	NXXTWWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjQO\|RKSzVyPUCuNVA{PDdizszN	MVfTRW5ITVJ?
NB69	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PVSGlEPTB;MD6xN\|Uh\|ryP	MYHTRW5ITVJ?
EGI-1	M2nUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTwR4JKSzVyPUCuNVM2OzFizszN	NGjyOWdUSU6JRWK=
EW-18	M1LmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nhN2lEPTB;MD6xOFA4OyEQvF2=	MXzTRW5ITVJ?
ME-180	M4L4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13jfWlEPTB;MD6xOFY5OSEQvF2=	MVjTRW5ITVJ?
D-283MED	NEXoNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7ETWM2OD1yLkG0O\|I{KM7:TR?=	NUHYV3FzW0GQR1XS
NB14	NUK4eVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrRTWM2OD1yLkG2OFQ4KM7:TR?=	MnezV2FPT0WU
Ramos-2G6-4C10	NWfnTJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPGTWM2OD1yLkG2PVg{KM7:TR?=	NFXxeW1USU6JRWK=
NBsusSR	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTBwMUewNVkh\|ryP	M13renNCVkeHUh?=
LAMA-84	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nVTGlEPTB;MD6xPFA{OiEQvF2=	MmT2V2FPT0WU
NCI-H1581	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMUi5OlYh\|ryP	NVflZXozW0GQR1XS
A204	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP4bmdKSzVyPUCuNVg6PyEQvF2=	NHzsdXhUSU6JRWK=
A549	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL1VmJUUUN3ME2wMlE6PTVizszN	NILGUWNUSU6JRWK=
CAL-51	NYT5VVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTBwMUm2OVEh\|ryP	NXOycXhoW0GQR1XS
NKM-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3oTWM2OD1yLkKwNFI6KM7:TR?=	MXLTRW5ITVJ?
LoVo	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWftZ\|JNUUN3ME2wMlIxOjB{IN88US=>	NVTWTXJKW0GQR1XS
HAL-01	M17KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrKcpFKSzVyPUCuNlAzQTdizszN	NGLRbHlUSU6JRWK=
HCC2218	NXT3UGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwMkC2PFgh\|ryP	MXPTRW5ITVJ?
BEN	M3r5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkP6TWM2OD1yLkKxNlk{KM7:TR?=	MXPTRW5ITVJ?
LC-2-ad	NGfRNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\VZZBKSzVyPUCuNlIxQDRizszN	Ml7MV2FPT0WU
LXF-289	NXL6SVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP1[FJsUUN3ME2wMlI2ODRzIN88US=>	MoH4V2FPT0WU
HGC-27	M4jWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\iTWM2OD1yLkK2OFE1KM7:TR?=	MXXTRW5ITVJ?
LK-2	NIjIcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DDW2lEPTB;MD6yOlgzPCEQvF2=	MmTzV2FPT0WU
CTB-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rMV2lEPTB;MD6yO\|IyPSEQvF2=	NV3FflI1W0GQR1XS
697	M1iwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1n5[mlEPTB;MD6yO\|M3PyEQvF2=	M3XrWXNCVkeHUh?=
ES7	NUnOe28{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXOR45KSzVyPUCuNlc{QDNizszN	NGPoRnhUSU6JRWK=
MG-63	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LGXGlEPTB;MD6yO\|QxPyEQvF2=	M{jGZnNCVkeHUh?=
T47D	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\4UlNKSzVyPUCuNlc1PzVizszN	M4fESXNCVkeHUh?=
RPMI-8226	NU\Id5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[4TWM2OD1yLkK4OVg6KM7:TR?=	NHXVWmVUSU6JRWK=
NCI-H292	M3m4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nEdmlEPTB;MD6yPVE3PCEQvF2=	NYDFSXhvW0GQR1XS
HT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwMkmzPEDPxE1?	MkKwV2FPT0WU
A3-KAW	NGHocpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwMkm3OEDPxE1?	Mmq3V2FPT0WU
LB2241-RCC	NXvzenJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwM{CxPVgh\|ryP	NIjYRZJUSU6JRWK=
BB65-RCC	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;SNHJHUUN3ME2wMlMxQDB3IN88US=>	MnnjV2FPT0WU
G-401	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfWSI9KSzVyPUCuN\|A6QDZizszN	M{TMTXNCVkeHUh?=
TYK-nu	M3z6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwM{G4OlQh\|ryP	M135bHNCVkeHUh?=
NCI-SNU-1	NXHTSpNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwM{KzN\|Eh\|ryP	MoOyV2FPT0WU
CHL-1	NInafYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHlVYtKSzVyPUCuN\|I4ODNizszN	M1fFUXNCVkeHUh?=
P30-OHK	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMWHFxUUN3ME2wMlMzPzB3IN88US=>	M1jyTnNCVkeHUh?=
PA-1	M3;YOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorGTWM2OD1yLkOzOlE6KM7:TR?=	MlP1V2FPT0WU
LB1047-RCC	M{KxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTBwM{SwOFch\|ryP	NWP2[HJDW0GQR1XS
EM-2	NID1XIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYH1W4FoUUN3ME2wMlM1OTh6IN88US=>	NYjvZ5J5W0GQR1XS
VA-ES-BJ	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jIcmlEPTB;MD6zOFI3QCEQvF2=	M{nvcnNCVkeHUh?=
NCI-H520	NVrYSXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jEVWlEPTB;MD6zOFg{PCEQvF2=	MnTJV2FPT0WU
ECC10	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTBwM{WwN\|Uh\|ryP	NXruVlVsW0GQR1XS
LNCaP-Clone-FGC	NELLW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfoTWM2OD1yLkO1N\|E1KM7:TR?=	MWHTRW5ITVJ?
ES8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETqXIdKSzVyPUCuN\|Y2PTNizszN	M4PhRXNCVkeHUh?=
HuO-3N1	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDUb3lMUUN3ME2wMlM5Ozd7IN88US=>	MnnnV2FPT0WU
L-363	NVzqPYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwM{mwNlYh\|ryP	Mm\oV2FPT0WU
SK-LU-1	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnx[HNZUUN3ME2wMlM6OjB6IN88US=>	M2D6ZXNCVkeHUh?=
MCF7	NHzuOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL4eGpKSzVyPUCuOFA2OyEQvF2=	MVPTRW5ITVJ?
HuO9	M1jlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGe0VFhKSzVyPUCuOFA3PjdizszN	NGfIU\|NUSU6JRWK=
BHT-101	NVjuXHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTBwNEC3PFch\|ryP	NXXQNXBIW0GQR1XS
MZ2-MEL	M3rOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[yOmlEPTB;MD60NFg5OiEQvF2=	MofpV2FPT0WU
NOS-1	NVTvU3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnmWVZRUUN3ME2wMlQyODd2IN88US=>	M1G3NXNCVkeHUh?=
NEC8	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;wNWlEPTB;MD60NVY6PSEQvF2=	NHjYWXRUSU6JRWK=
COR-L88	NYfnWpd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LrUmlEPTB;MD60NlI3PyEQvF2=	M2rySXNCVkeHUh?=
MFM-223	NX;LOFZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwNEK2NVch\|ryP	M2nLeXNCVkeHUh?=
HSC-3	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGP0PXZKSzVyPUCuOFI6ODhizszN	NIm2e3JUSU6JRWK=
OVCAR-5	M4HJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fReGlEPTB;MD60Nlk{OyEQvF2=	NGXWOWZUSU6JRWK=
MFE-280	NHXMW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHYTWM2OD1yLkSzNFMzKM7:TR?=	MnPkV2FPT0WU
KP-N-YS	NGL4dppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jTPGlEPTB;MD60N\|A4KM7:TR?=	MVvTRW5ITVJ?
EPLC-272H	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[1TWM2OD1yLkSzNFc4KM7:TR?=	M3PJN3NCVkeHUh?=
KE-37	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzXTWM2OD1yLkSzNlQ4KM7:TR?=	MnfrV2FPT0WU
HuH-7	M3jZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LlTmlEPTB;MD60N\|M4OiEQvF2=	NUCwUGFzW0GQR1XS
CHP-212	NFzTdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzwTFNKSzVyPUCuOFM3QTdizszN	NUjocWZNW0GQR1XS
SK-MES-1	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTBwNEO4OFgh\|ryP	NFLESotUSU6JRWK=
SJSA-1	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnDdFlKSzVyPUCuOFQ2PTRizszN	NF7zSZFUSU6JRWK=
QIMR-WIL	M4O5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnIblFUUUN3ME2wMlQ2OTVizszN	MVfTRW5ITVJ?
ES4	NF;MWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv3dXhGUUN3ME2wMlQ2OzN4IN88US=>	MVzTRW5ITVJ?
TI-73	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnWTWM2OD1yLkS1Olg3KM7:TR?=	NH7WcZBUSU6JRWK=
COLO-684	M2e2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPIe4ZFUUN3ME2wMlQ2PzJ4IN88US=>	M3fMUHNCVkeHUh?=
GCIY	NHTlWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHiToJKSzVyPUCuOFU4PTRizszN	NX\BOVd7W0GQR1XS
JVM-3	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzH[4czUUN3ME2wMlQ3Ojl{IN88US=>	M2ri[XNCVkeHUh?=
MPP-89	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz0TWM2OD1yLkS2PVQ4KM7:TR?=	NFn0XIJUSU6JRWK=
M14	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXVOZk6UUN3ME2wMlQ4OTdizszN	MkjaV2FPT0WU
SW962	NIK3WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwNEexPUDPxE1?	MmnJV2FPT0WU
VM-CUB-1	NYnib4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u5VmlEPTB;MD60O\|I5PiEQvF2=	MUnTRW5ITVJ?
A101D	NGHaeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7aSVZKSzVyPUCuOFg6PjhizszN	MV3TRW5ITVJ?
DB	NV;Ofmt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwNUCwNlEh\|ryP	M3zGdnNCVkeHUh?=
KNS-62	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3sco5rUUN3ME2wMlUxPTZ6IN88US=>	NF;vRVhUSU6JRWK=
NCI-H460	M4e3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7uUYxYUUN3ME2wMlUxPTl5IN88US=>	MXnTRW5ITVJ?
MDA-MB-361	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7qTWM2OD1yLkWwPFch\|ryP	NWP4XG9SW0GQR1XS
DOK	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nTUGlEPTB;MD61NVM{OyEQvF2=	MWXTRW5ITVJ?
CAL-39	NXGyOWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTBwNUKyOlgh\|ryP	NIWzTFZUSU6JRWK=
HT-1080	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7YNZMxUUN3ME2wMlUzPTR\|IN88US=>	NU\mTFVwW0GQR1XS
GR-ST	M1rJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:zNWhKSzVyPUCuOVMxOTVizszN	NFvxV\|hUSU6JRWK=
J-RT3-T3-5	NEX6VG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13vW2lEPTB;MD61N\|E6PSEQvF2=	NF;SV2FUSU6JRWK=
NCI-H1793	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTBwNUO0OFch\|ryP	NVT2U\|BuW0GQR1XS
NCI-H1355	NITRZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3VWlFvUUN3ME2wMlU{QDd6IN88US=>	NGKwT\|VUSU6JRWK=
YH-13	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnrT3VLUUN3ME2wMlU1QTN6IN88US=>	M{H2WnNCVkeHUh?=
LOXIMVI	NEP5XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fVRWlEPTB;MD61OVEzOyEQvF2=	MkjuV2FPT0WU
ES1	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHKxSVlKSzVyPUCuOVU2OThizszN	MYjTRW5ITVJ?
GAMG	M4q0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vhe2lEPTB;MD61OVY2QCEQvF2=	MV\TRW5ITVJ?
SK-MEL-28	NYfseHdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHyTWM2OD1yLkW1PVEh\|ryP	MnrsV2FPT0WU
KG-1	NUTRTXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwNU[4PFQh\|ryP	M3e3[HNCVkeHUh?=
HOS	M1znSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfaTWM2OD1yLkW3NVkzKM7:TR?=	NVfaU3hSW0GQR1XS
PANC-08-13	NFH4fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHsOI1KSzVyPUCuOVc{QDlizszN	Mk\lV2FPT0WU
SW780	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITH[YRKSzVyPUCuOVc2QTVizszN	MnjWV2FPT0WU
MDA-MB-175-VII	M1naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKzdY5KSzVyPUCuOVc4PDFizszN	NFTCSotUSU6JRWK=
MSTO-211H	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwNUe3OVEh\|ryP	NYLDcpNQW0GQR1XS
ML-2	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm4TWM2OD1yLkW4OFc5KM7:TR?=	NVvoRppOW0GQR1XS
SCC-4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HXb2lEPTB;MD61PFU1OSEQvF2=	NVnocGRmW0GQR1XS
NCI-H1048	M3n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPIZYJKSzVyPUCuOVg3PDVizszN	NYT1S4ZZW0GQR1XS
NCI-H28	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPpTWM2OD1yLkW4Olc2KM7:TR?=	MlPjV2FPT0WU
BCPAP	NYm0U\|QxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qwOWlEPTB;MD61PFc6OSEQvF2=	NVXYUWs6W0GQR1XS
PC-14	NFnrPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[zUWlEPTB;MD61PFk4KM7:TR?=	MVLTRW5ITVJ?
OAW-42	NXrFNpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwNUmxOlIh\|ryP	MWXTRW5ITVJ?
IA-LM	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDmTWM2OD1yLkW5OlA6KM7:TR?=	NHixc49USU6JRWK=
Hs-578-T	NIHQU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXJTWM2OD1yLkW5PFUyKM7:TR?=	MUDTRW5ITVJ?
H4	NYLWWWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HKRmlEPTB;MD62NFA6PCEQvF2=	NFX2WJBUSU6JRWK=
HL-60	NHLVempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\lNGlKSzVyPUCuOlA{PTFizszN	MVnTRW5ITVJ?
NCI-H1437	NEHsb\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\Id4ZKSzVyPUCuOlA3OTlizszN	Mk\2V2FPT0WU
KGN	NEPPdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUj6Tm97UUN3ME2wMlYyODR7IN88US=>	M3LIVXNCVkeHUh?=
NCI-H2452	NWjRcXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LpcWlEPTB;MD62NVkyPyEQvF2=	NEHFc49USU6JRWK=
BFTC-905	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwNkKxNlYh\|ryP	NXHKWndxW0GQR1XS
CAMA-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HyXGlEPTB;MD62NlE2OiEQvF2=	MmmzV2FPT0WU
SK-NEP-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTBwNkK1NFIh\|ryP	NYLZbpF6W0GQR1XS
NCI-H522	M4X1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnPTWM2OD1yLk[yPVkzKM7:TR?=	MWrTRW5ITVJ?
SW1710	NXjTV29XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfkS2dKSzVyPUCuOlMyPjdizszN	NEfxSm1USU6JRWK=
RVH-421	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUL6OHNwUUN3ME2wMlY{PjN7IN88US=>	M1\4[HNCVkeHUh?=
SK-MEL-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTBwNkSxOVMh\|ryP	MoXGV2FPT0WU
KYSE-150	NUnzNIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwNk[xPFYh\|ryP	MmfSV2FPT0WU
MOLT-13	M4T2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi4N3RKSzVyPUCuOlY2OzdizszN	NIjjVpFUSU6JRWK=
SK-OV-3	M4\2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe0S4FKSzVyPUCuOlcyQDdizszN	MoexV2FPT0WU
IGROV-1	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfBTWM2OD1yLk[3OFUh\|ryP	Mn23V2FPT0WU
MOLT-4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XkV2lEPTB;MD62O\|Y5QSEQvF2=	NEHp[2hUSU6JRWK=
MEL-HO	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHn4fY9KSzVyPUCuOlc4PTJizszN	NF62VJRUSU6JRWK=
MDA-MB-157	NUX3[lExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTEdlBkUUN3ME2wMlY4QDFizszN	MXzTRW5ITVJ?
MN-60	NX;qWYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLOdoQ1UUN3ME2wMlY4QDR4IN88US=>	M2HUV3NCVkeHUh?=
EFO-27	NVv3eFQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTBwNke5O\|kh\|ryP	NGDxRZdUSU6JRWK=
HO-1-N-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjvTWM2OD1yLk[4NFY1KM7:TR?=	NESybZRUSU6JRWK=
TE-5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rkcGlEPTB;MD62PFQxPSEQvF2=	NV:y[5N4W0GQR1XS
EW-22	NYLpeVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjHd2hRUUN3ME2wMlY5PDR2IN88US=>	MnPPV2FPT0WU
SW982	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnZTopiUUN3ME2wMlY5PTBzIN88US=>	NVzwVG86W0GQR1XS
SF295	M{HNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTBwNki1NFch\|ryP	MYPTRW5ITVJ?
WM-115	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwNki5NlQh\|ryP	MWHTRW5ITVJ?
COLO-800	NUXhW2JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3mxXmlEPTB;MD62PVgyOyEQvF2=	NWXQfnZMW0GQR1XS
NTERA-S-cl-D1	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rqVWlEPTB;MD63NFA3OyEQvF2=	M4XDR3NCVkeHUh?=
NCI-H1648	M4m0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPKTWM2OD1yLkewNVc{KM7:TR?=	MkHDV2FPT0WU
NB5	NUf4dppwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH33UYRKSzVyPUCuO\|A{OTlizszN	NIHVNndUSU6JRWK=
ATN-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrDTG5KSzVyPUCuO\|A2QSEQvF2=	NVn1N\|JbW0GQR1XS
NUGC-3	NGnneZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\TWZVKSzVyPUCuO\|A3QTFizszN	MV7TRW5ITVJ?
22RV1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTBwN{C3NVch\|ryP	M3Lvb3NCVkeHUh?=
8305C	M3fmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7ITWM2OD1yLkewO\|U2KM7:TR?=	M1XOZXNCVkeHUh?=
EFM-19	NEPXdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHvTWM2OD1yLkewPFQ4KM7:TR?=	NIDIbXZUSU6JRWK=
PC-3	NFzFb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPkTWM2OD1yLkeyNlMh\|ryP	NUPGOXpEW0GQR1XS
C32	M3riOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3UTmJGUUN3ME2wMlczPDh2IN88US=>	MnHuV2FPT0WU
MC-IXC	NFnUPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7XOY14UUN3ME2wMlczPzF6IN88US=>	NUT6V\|gzW0GQR1XS
OMC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTBwN{K3N\|gh\|ryP	MY\TRW5ITVJ?
HTC-C3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrJTWM2OD1yLkezNVczKM7:TR?=	MYPTRW5ITVJ?
RPMI-7951	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjPVnpMUUN3ME2wMlc{PTN\|IN88US=>	NF76V2VUSU6JRWK=
AsPC-1	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTBwN{O3PVUh\|ryP	NInObJBUSU6JRWK=
CAKI-1	NUDxRlNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvtbYtKSzVyPUCuO\|Q3OjlizszN	M1j1VXNCVkeHUh?=
MHH-PREB-1	NHLjN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXYUZNKSzVyPUCuO\|Q4OzZizszN	NXzsfXFlW0GQR1XS
HLE	M3rTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfmTWM2OD1yLke0PFQ1KM7:TR?=	Ml3NV2FPT0WU
A375	NYGyc4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGroRpBKSzVyPUCuO\|UyQTNizszN	NWewdJc2W0GQR1XS
RS4-11	NW\KRXlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfSTWM2OD1yLke1PVQ{KM7:TR?=	MXfTRW5ITVJ?
U-2-OS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzMTWM2OD1yLke1PVch\|ryP	MofEV2FPT0WU
NCI-H747	NXrtOpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwN{W5PVEh\|ryP	NYPWOVUxW0GQR1XS
NCI-H1623	M4PUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwN{[yOlEh\|ryP	NVLabJJkW0GQR1XS
DMS-273	M3jCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXkVGRNUUN3ME2wMlc3QTJ{IN88US=>	MlTmV2FPT0WU
PSN1	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELzPGNKSzVyPUCuO\|cxPTdizszN	NH;LZnVUSU6JRWK=
LU-99A	M{HYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf1UnhKSzVyPUCuO\|c3PDlizszN	NXra[mhPW0GQR1XS
CAL-12T	M3npb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX6wVGVvUUN3ME2wMlc5ODJ7IN88US=>	M1zU[nNCVkeHUh?=
KYSE-140	NX;QO3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7jWYRyUUN3ME2wMlc5OTZ6IN88US=>	MVXTRW5ITVJ?
VMRC-RCZ	M4rUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTBwN{i0PFIh\|ryP	M1j6NXNCVkeHUh?=
Ca9-22	M1Wx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\hbnV2UUN3ME2wMlc5PzN4IN88US=>	NVHURYdbW0GQR1XS
NCI-H1563	NYXVTmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnyN\|ZKSzVyPUCuO\|g6OjZizszN	M3iw[3NCVkeHUh?=
NCI-H650	M4PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwN{mxOFQh\|ryP	NFjh[3JUSU6JRWK=
DOHH-2	M2juNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TXPGlEPTB;MD63PVM{KM7:TR?=	NHvYRYpUSU6JRWK=
OE33	NV7ZcnhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjwR4k5UUN3ME2wMlc6QTF2IN88US=>	NWHxT2luW0GQR1XS
CAL-62	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGmzOWZKSzVyPUCuO\|k6OjRizszN	M1PX[nNCVkeHUh?=
NCI-H1770	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXniXZlJUUN3ME2wMlgxOjFizszN	M4XtTXNCVkeHUh?=
SN12C	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwOEC2Olgh\|ryP	MmXpV2FPT0WU
HPAF-II	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLVfZdjUUN3ME2wMlgxPzl2IN88US=>	NXHyUIJYW0GQR1XS
SNU-423	M4GzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PsU2lEPTB;MD64NVQzOiEQvF2=	M3PtR3NCVkeHUh?=
A704	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\YTWM2OD1yLkixO\|k5KM7:TR?=	MlH2V2FPT0WU
OVCAR-4	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPqTWM2OD1yLkixPVEyKM7:TR?=	NFzFNo1USU6JRWK=
NCI-H2347	NUDyV3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwOEK0NFEh\|ryP	MnjQV2FPT0WU
OCUB-M	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;XZ4FHUUN3ME2wMlgzPjd3IN88US=>	NILVXJlUSU6JRWK=
KYSE-450	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXRR2FzUUN3ME2wMlgzPzJ3IN88US=>	MUDTRW5ITVJ?
PFSK-1	NIXVU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwOEOwN\|kh\|ryP	NUnlOnR5W0GQR1XS
A431	M4fFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPxTWM2OD1yLkizNVE3KM7:TR?=	MnOyV2FPT0WU
MHH-ES-1	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom4TWM2OD1yLkizOFU4KM7:TR?=	MlTUV2FPT0WU
HD-MY-Z	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rOUGlEPTB;MD64OFA6OiEQvF2=	NWnicZNDW0GQR1XS
RT-112	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzIWVFKSzVyPUCuPFQ6OzdizszN	Moi4V2FPT0WU
KU-19-19	NEfWdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXXRWVKSzVyPUCuPFUyOjFizszN	MWrTRW5ITVJ?
HCC1569	NEnYSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKxcIJEUUN3ME2wMlg2OjB5IN88US=>	NWfMPZZCW0GQR1XS
RPMI-8866	NH;Zc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwOEW4NlIh\|ryP	MUPTRW5ITVJ?
CAL-120	M3j6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7wTWM2OD1yLki2NFQyKM7:TR?=	MkfQV2FPT0WU
CAL-33	M1W3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HLOmlEPTB;MD64OlQ6PSEQvF2=	M165U3NCVkeHUh?=
RKO	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTBwOE[4NVch\|ryP	M2LzO3NCVkeHUh?=
HCC1419	M3;HVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrRem9KUUN3ME2wMlg3QTJ6IN88US=>	NIfxUlRUSU6JRWK=
CP50-MEL-B	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXQcoV2UUN3ME2wMlg5Ozh2IN88US=>	NWPpTWpFW0GQR1XS
BPH-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Tpc2lEPTB;MD64PFM6PSEQvF2=	M4rDWnNCVkeHUh?=
SF126	NHnQbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3CV3FKSzVyPUCuPFg4OTRizszN	MmrlV2FPT0WU
BHY	M{\rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PmR2lEPTB;MD64PFc{PCEQvF2=	NELvUW9USU6JRWK=
BxPC-3	NW\IUoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS3TWM2OD1yLki4PFM{KM7:TR?=	MXzTRW5ITVJ?
ETK-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nZTWlEPTB;MD64PVM4OiEQvF2=	MVXTRW5ITVJ?
NCI-H1573	NX62T\|U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwOUCyNlkh\|ryP	NE\vW3lUSU6JRWK=
C-33-A	M3LTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHsVYxZUUN3ME2wMlkxPDR{IN88US=>	Mn61V2FPT0WU
UACC-893	NHqzVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXKb3k2UUN3ME2wMlkzQDV3IN88US=>	M3HBfnNCVkeHUh?=
RXF393	M2XkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnE[Vl1UUN3ME2wMlkzQDl5IN88US=>	MWrTRW5ITVJ?
MIA-PaCa-2	M3zPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dm[WlEPTB;MD65NlkzOiEQvF2=	NWXiNZRGW0GQR1XS
HCC1806	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DGU2lEPTB;MD65N\|I2PiEQvF2=	MX;TRW5ITVJ?
DMS-114	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfLcVFKSzVyPUCuPVM3PzdizszN	MmPZV2FPT0WU
MOLT-16	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLmR\|NKSzVyPUCuPVM5PDVizszN	NEjncWxUSU6JRWK=
ACN	NWSwfGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z6fmlEPTB;MD65OFI4PyEQvF2=	NXW5ZmRiW0GQR1XS
SNU-449	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjYenllUUN3ME2wMlk2QTJ2IN88US=>	NEPUWVhUSU6JRWK=
A427	M{nwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXPWWZKSzVyPUCuPVYyQThizszN	NVjXepUxW0GQR1XS
DEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojMTWM2OD1yLkm2O\|c{KM7:TR?=	M1LFdHNCVkeHUh?=
NCI-H1792	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf3R3ZpUUN3ME2wMlk4OTBzIN88US=>	NFHLRlhUSU6JRWK=
A2058	NHP2cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELZWYtKSzVyPUCuPVc{PiEQvF2=	Mne1V2FPT0WU
SW13	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFy0V21KSzVyPUCuPVg{QTJizszN	Mnz2V2FPT0WU
T98G	NITjSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFmyR5BKSzVyPUGuNFE{PjRizszN	MV7TRW5ITVJ?
LU-134-A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjWfpdbUUN3ME2xMlAzPjd3IN88US=>	M33ZN3NCVkeHUh?=
GI-ME-N	M{Xqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\FUm9HUUN3ME2xMlAzQDJ5IN88US=>	NYH0bIx2W0GQR1XS
D-423MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFwMEK5OlMh\|ryP	MX\TRW5ITVJ?
PANC-03-27	NWKydHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\lWWJJUUN3ME2xMlA{OTRzIN88US=>	NVfQ[XZSW0GQR1XS
P12-ICHIKAWA	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{naSmlEPTB;MT6wN\|QxPiEQvF2=	MkXWV2FPT0WU
SCH	NIjnT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV33WHZ5UUN3ME2xMlA{PDVizszN	MnO1V2FPT0WU
D-566MG	NUTHRVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln2TWM2OD1zLkC2O\|I3KM7:TR?=	NW\n[HVMW0GQR1XS
OS-RC-2	M2TwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\ZTWM2OD1zLkC3PVQh\|ryP	NV25N5BRW0GQR1XS
KOSC-2	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTFwMEiwNlEh\|ryP	MYXTRW5ITVJ?
SH-4	NF;scZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Tn[2lEPTB;MT6wPFQ{OSEQvF2=	Ml\EV2FPT0WU
786-0	NFP2OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1uxXmlEPTB;MT6wPFk{PCEQvF2=	NHXkPWJUSU6JRWK=
Mewo	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEWycGRKSzVyPUGuNFkzPDhizszN	MlfGV2FPT0WU
AGS	M{nQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3GV4ZlUUN3ME2xMlA6PDV7IN88US=>	MkP0V2FPT0WU
Daoy	NHm3TohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTCTWM2OD1zLkC5OlI5KM7:TR?=	M37SRXNCVkeHUh?=
SW48	NHzUS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPzTWM2OD1zLkGwPVEyKM7:TR?=	MnjQV2FPT0WU
KYSE-180	NFi2N\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnOVXNKSzVyPUGuNVExOjFizszN	NEfvZWNUSU6JRWK=
NH-12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfqXY1KSzVyPUGuNVEzOzdizszN	M324[nNCVkeHUh?=
BE-13	M4ixZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTFwMUG3OVkh\|ryP	NEfTcYJUSU6JRWK=
ES3	NXG5Oo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mli1TWM2OD1zLkGzNVcyKM7:TR?=	NH7nblZUSU6JRWK=
NCI-H1092	NVG1dY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrtTWM2OD1zLkGzOEDPxE1?	NWrYUHZlW0GQR1XS
NCI-H1755	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LwbGlEPTB;MT6xN\|k1OSEQvF2=	NWnr[4VuW0GQR1XS
EKVX	NWnDc3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3JUGdKSzVyPUGuNVQxODFizszN	M3HPNXNCVkeHUh?=
NB13	NWDJW5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwMUS0OUDPxE1?	MVTTRW5ITVJ?
NCI-H2405	NIPFVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTvTWM2OD1zLkG0OVc1KM7:TR?=	NIjqR5NUSU6JRWK=
LS-411N	M4[zNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwMUWwNVch\|ryP	NHy1SplUSU6JRWK=
MDA-MB-453	NI[xd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTxTWM2OD1zLkG1OlI1KM7:TR?=	M1Tw[XNCVkeHUh?=
SCC-15	NGX0TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzwUZVKSzVyPUGuNVY6PTZizszN	MYHTRW5ITVJ?
C2BBe1	NYLwSll3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\6[opWUUN3ME2xMlE4ODV4IN88US=>	NEnaW49USU6JRWK=
HT-144	MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXIcm9KSzVyPUGuNVcxPyEQvF2=	M3XSZXNCVkeHUh?=
HEC-1	NWfocoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTFwMUe2Nlch\|ryP	NIrVWnRUSU6JRWK=
HCE-T	NEHEcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnKTWM2OD1zLkG3PVg{KM7:TR?=	NWnzd2EzW0GQR1XS
IST-MEL1	NHzEU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NICyWHlKSzVyPUGuNVkxQDJizszN	MUDTRW5ITVJ?
Detroit562	NYH4THRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfD[GZFUUN3ME2xMlE6PDN7IN88US=>	MWPTRW5ITVJ?
A4-Fuk	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7pTWM2OD1zLkKwOFQyKM7:TR?=	MWTTRW5ITVJ?
HDLM-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\oemVKSzVyPUGuNlE{OjZizszN	MlO0V2FPT0WU
MKN7	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzpTWM2OD1zLkKxO\|AzKM7:TR?=	NVrsWYJwW0GQR1XS
MDA-MB-415	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PVWWlEPTB;MT6yNVcxOiEQvF2=	Mlr2V2FPT0WU
BT-20	NIK3UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEG3VodKSzVyPUGuNlI1PDRizszN	M3HjO3NCVkeHUh?=
NCI-H2030	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jybWlEPTB;MT6yOFExPiEQvF2=	NWfFTIp5W0GQR1XS
LS-123	NIX6SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwMkS3OVMh\|ryP	M1z5bnNCVkeHUh?=
SK-MEL-3	NHHNbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\FZod[UUN3ME2xMlI1Pzd4IN88US=>	NYnMTlFZW0GQR1XS
KS-1	NUL5U4RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnK5TWM2OD1zLkK1NVcyKM7:TR?=	MY\TRW5ITVJ?
LU-65	M3fnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTvNIpKSzVyPUGuNlU3ODZizszN	NHPsbZlUSU6JRWK=
NCI-H596	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLTTWM2OD1zLkK1PVI6KM7:TR?=	NH;McmZUSU6JRWK=
KYSE-410	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwMkewNVQh\|ryP	MmjvV2FPT0WU
NCI-H2228	NELyNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XyOWlEPTB;MT6yO\|E3PyEQvF2=	NUHweIFGW0GQR1XS
LN-405	NEnz[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwMkiwNlEh\|ryP	NFXidGhUSU6JRWK=
8505C	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrWZolTUUN3ME2xMlI5QDJ\|IN88US=>	MWDTRW5ITVJ?
BFTC-909	M1G0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUSzNWl5UUN3ME2xMlI6PDN2IN88US=>	NHnpSWhUSU6JRWK=
OC-314	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TTcGlEPTB;MT6yPVkzQSEQvF2=	NXTiflVkW0GQR1XS
NMC-G1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ywRmlEPTB;MT6zNVE{PSEQvF2=	MofsV2FPT0WU
SKG-IIIa	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHCeZg6UUN3ME2xMlMyPDJ6IN88US=>	MYHTRW5ITVJ?
GAK	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPHVHFKSzVyPUGuN\|E5PThizszN	MmDkV2FPT0WU
D-263MG	M{DzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPyT5JKSzVyPUGuN\|I3PDFizszN	MXXTRW5ITVJ?
NCI-H446	NVzKS2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfJeZFKSzVyPUGuN\|I6ODJizszN	M4nN[nNCVkeHUh?=
TGBC1TKB	M{XZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFyxPI5KSzVyPUGuN\|I6QThizszN	MVjTRW5ITVJ?
GCT	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfv[m1KSzVyPUGuN\|Q{PDVizszN	MWPTRW5ITVJ?
COR-L23	NFfCO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwM{S4OFUh\|ryP	NXfCUW5ZW0GQR1XS
TK10	NUfGTnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\hTWM2OD1zLkO1O\|k4KM7:TR?=	NUWyeoxZW0GQR1XS
ES6	M3LrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwM{[zO\|Yh\|ryP	NV7TNWtYW0GQR1XS
SW1088	NGTteYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XQXGlEPTB;MT6zOlYyOiEQvF2=	NEnFS4RUSU6JRWK=
AM-38	M2XER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nwPWlEPTB;MT6zO\|E6QSEQvF2=	M4HEe3NCVkeHUh?=
CHP-134	M3G1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXJTWM2OD1zLkO3PFQ1KM7:TR?=	MYTTRW5ITVJ?
SW872	NUDXRm1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwM{i1OVUh\|ryP	MojIV2FPT0WU
LB831-BLC	M1HzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTHVmFEUUN3ME2xMlM6ODZ5IN88US=>	Mn3vV2FPT0WU
TE-12	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnewTWM2OD1zLkSwOlAyKM7:TR?=	NUe3UXZJW0GQR1XS
LCLC-97TM1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{m1dGlEPTB;MT60NVA1PiEQvF2=	MkTkV2FPT0WU
HCT-116	NHTCTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnBe2pVUUN3ME2xMlQzQDV2IN88US=>	NIPjfIpUSU6JRWK=
ALL-PO	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlviTWM2OD1zLkSzO\|c1KM7:TR?=	NV;VVYJPW0GQR1XS
EW-16	M1PtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4CwfWlEPTB;MT60N\|g1OiEQvF2=	MnvrV2FPT0WU
NCI-H661	NEXIR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHRTWM2OD1zLkS0O\|c2KM7:TR?=	NXj3bWc3W0GQR1XS
TE-8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFwNEW1OkDPxE1?	NIH6dWxUSU6JRWK=
TCCSUP	NV[zSJZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC3TWM2OD1zLkS2PVYh\|ryP	MVLTRW5ITVJ?
SW1990	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXO5OFNCUUN3ME2xMlQ4PTN\|IN88US=>	MULTRW5ITVJ?
UM-UC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTrXHA5UUN3ME2xMlQ4Pjd3IN88US=>	M3HRRnNCVkeHUh?=
HuP-T4	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTFwNEi2NFch\|ryP	M3fKVHNCVkeHUh?=
NCI-H1299	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfq[5pKSzVyPUGuOVAxQDZizszN	MmjiV2FPT0WU
RO82-W-1	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nnXGlEPTB;MT61NlA5OSEQvF2=	NGPYOG5USU6JRWK=
Becker	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnP5TWM2OD1zLkWyNVg4KM7:TR?=	M4T1WnNCVkeHUh?=
SNU-387	M4HwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnPdnJGUUN3ME2xMlUzOjRzIN88US=>	NGfxTmRUSU6JRWK=
CAL-85-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33OW2lEPTB;MT61NlU6QSEQvF2=	MXjTRW5ITVJ?
647-V	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwNUO4PEDPxE1?	MmjaV2FPT0WU
SBC-5	NUfnbWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIe0XnFKSzVyPUGuOVQ2QTNizszN	NFXVNmRUSU6JRWK=
NCI-H23	M2LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFwNUW3NVQh\|ryP	MWHTRW5ITVJ?
CGTH-W-1	M4nkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLHSVUxUUN3ME2xMlU2QDF7IN88US=>	MV\TRW5ITVJ?
SK-N-FI	NXzUWm16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTFwNUW5NFgh\|ryP	MnrDV2FPT0WU
KM-H2	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi2[nFKSzVyPUGuOVY1PzRizszN	M17idXNCVkeHUh?=
KY821	NF;3XWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLIUFJQUUN3ME2xMlU3PjF5IN88US=>	NILIbpBUSU6JRWK=
RH-1	M{HnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\CU2pKSzVyPUGuOVY4PjJizszN	M{XobnNCVkeHUh?=
KYSE-270	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDmU2RKSzVyPUGuOVc1OjNizszN	MV\TRW5ITVJ?
SF539	NHHBcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwNUe5Olkh\|ryP	MlzDV2FPT0WU
JEG-3	NELxT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TM[GlEPTB;MT61PFA6PCEQvF2=	NHv2fm1USU6JRWK=
SCC-25	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTFwNUi0N\|Ih\|ryP	MVXTRW5ITVJ?
SW1573	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPITWM2OD1zLk[wNVU5KM7:TR?=	NHfDXohUSU6JRWK=
EW-1	M2H2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPkOZZkUUN3ME2xMlYyOzVzIN88US=>	M2DMbXNCVkeHUh?=
YKG-1	NF;FO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPZe4FKSzVyPUGuOlE1OzhizszN	NVP1fpdtW0GQR1XS
EW-11	NG\qdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTOTWM2OD1zLk[xO\|QyKM7:TR?=	M2nUNnNCVkeHUh?=
DJM-1	M1HHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG5dpNZUUN3ME2xMlYyQDJ3IN88US=>	MlHUV2FPT0WU
Calu-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnWTWM2OD1zLk[1NlE{KM7:TR?=	M4L5VXNCVkeHUh?=
HT-3	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X6[2lEPTB;MT62OVY3KM7:TR?=	MoS3V2FPT0WU
NCI-H69	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fiS2lEPTB;MT62O\|M1OyEQvF2=	NEHzSpNUSU6JRWK=
NCI-H2126	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXzfJV6UUN3ME2xMlY4Pzl5IN88US=>	MYDTRW5ITVJ?
RPMI-2650	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;Sb3dGUUN3ME2xMlY5OzF5IN88US=>	NVG4[o17W0GQR1XS
TE-6	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvPTmNiUUN3ME2xMlcxQDd2IN88US=>	MmnIV2FPT0WU
MDA-MB-231	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwN{G5PVMh\|ryP	NUKwb5p7W0GQR1XS
A2780	NXLCN41lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjFXmdCUUN3ME2xMlczOjB5IN88US=>	Mli1V2FPT0WU
GOTO	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLETWM2OD1zLkezOVYh\|ryP	NWnOTYFGW0GQR1XS
KYSE-70	NEfrW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwN{S0OFIh\|ryP	MVnTRW5ITVJ?
GMS-10	M2HQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PuSGlEPTB;MT63OFY3OiEQvF2=	MWrTRW5ITVJ?
CaR-1	NULTeFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTFwN{S4NVIh\|ryP	MVPTRW5ITVJ?
SW900	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3n2bGlEPTB;MT63OFk6OyEQvF2=	NXL0ZXdYW0GQR1XS
BB49-HNC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTFwN{WxOlgh\|ryP	M3nhPXNCVkeHUh?=
SNB75	NVnDS3p{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O4[WlEPTB;MT63OVQ6OiEQvF2=	Mni3V2FPT0WU
SK-PN-DW	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\Re3FmUUN3ME2xMlc2Pjh{IN88US=>	MnXWV2FPT0WU
5637	NYjIbGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorOTWM2OD1zLke3NlY5KM7:TR?=	NEfMbnJUSU6JRWK=
BT-474	NVrxO4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3GyfGlEPTB;MT63PFE4OSEQvF2=	NYDScZZ7W0GQR1XS
KM12	NFHNOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDWc\|BKSzVyPUGuO\|k4PDFizszN	MnHzV2FPT0WU
COLO-680N	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUn4UZB1UUN3ME2xMlgzOzhzIN88US=>	MlnkV2FPT0WU
Saos-2	NG[1NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwOEK0OFUh\|ryP	MmS0V2FPT0WU
CAL-54	NYW5eppVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEOySZBKSzVyPUGuPFM{OTNizszN	Ml[wV2FPT0WU
U-118-MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7R[5I3UUN3ME2xMlg1PjJ{IN88US=>	NHfQVIZUSU6JRWK=
TGBC24TKB	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzTV2VbUUN3ME2xMlg2PTBzIN88US=>	M3fJ[3NCVkeHUh?=
NCI-H2052	NXHTOIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFwOE[0NUDPxE1?	MYDTRW5ITVJ?
BB30-HNC	NGW0WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\EVoFUUUN3ME2xMlg3PDZ{IN88US=>	M1jQTXNCVkeHUh?=
KNS-81-FD	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\pflFKSzVyPUGuPFkyPjVizszN	MofvV2FPT0WU
HN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLucmJKSzVyPUGuPFk2PDVizszN	NF;VWmpUSU6JRWK=
ACHN	NUfwUoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwOUC3PFYh\|ryP	Ml3vV2FPT0WU
HSC-2	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTFwOUGwPVYh\|ryP	NVfUOJEyW0GQR1XS
HCC2998	M{[3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFwOUOzNlUh\|ryP	M{XQZ3NCVkeHUh?=
HEL	NG\YNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfwT3FKSzVyPUGuPVQyQDRizszN	Ml7pV2FPT0WU
SW684	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3iTWM2OD1zLkm3N\|cyKM7:TR?=	MmTzV2FPT0WU
NCI-H1693	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG4TWM2OD1zLkm4NFg3KM7:TR?=	NVrQflN[W0GQR1XS
8-MG-BA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLnUZhKSzVyPUGuPVgzOSEQvF2=	M{XPfHNCVkeHUh?=
OVCAR-8	M3;NU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGexZpNKSzVyPUKuNFAzQTVizszN	MniyV2FPT0WU
DSH1	M4\LTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID2Wm5KSzVyPUKuNFE4PzRizszN	MYrTRW5ITVJ?
KYSE-520	MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fGOWlEPTB;Mj6wNlA1QSEQvF2=	NVvHbpl4W0GQR1XS
GB-1	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJwMEK1O\|ch\|ryP	MXjTRW5ITVJ?
RCC10RGB	NI\oZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\hSFRKSzVyPUKuNFQ5PzFizszN	MnX1V2FPT0WU
SW954	NWLrcYtWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTJwMEWwN\|Yh\|ryP	MVnTRW5ITVJ?
IST-MES1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13BTWlEPTB;Mj6wOVU3QCEQvF2=	NWO3ZWF4W0GQR1XS
AU565	M2HtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwMEW5NFUh\|ryP	MXrTRW5ITVJ?
CW-2	NHnCXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLXTWM2OD1{LkC2PFc2KM7:TR?=	NEj1TmZUSU6JRWK=
TE-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfLS3JKSzVyPUKuNFk{PzdizszN	NUj0bmNuW0GQR1XS
KP-4	NVK5UlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJwMUCzNVIh\|ryP	Mm[1V2FPT0WU
SNU-C2B	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37W[mlEPTB;Mj6xNFgzOyEQvF2=	NH\uWWpUSU6JRWK=
NCI-H1395	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJwMUC5PFYh\|ryP	MWDTRW5ITVJ?
CAS-1	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJwMUG1OFYh\|ryP	NVnzWppNW0GQR1XS
NCI-H1155	NEPzdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLmb4dvUUN3ME2yMlIzPjlizszN	NHq3e5ZUSU6JRWK=
SK-MEL-1	NUXCTphZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLPfI1PUUN3ME2yMlI5OThzIN88US=>	NYrwZlU1W0GQR1XS
KINGS-1	NVHoZos5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXCTWM2OD1{LkOwNFg5KM7:TR?=	M{PsR3NCVkeHUh?=
ESS-1	NGrlRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJwM{C1NUDPxE1?	NUTJfWVOW0GQR1XS
PANC-10-05	NXfCUoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fTNGlEPTB;Mj6zO\|AzPCEQvF2=	M3rvcnNCVkeHUh?=
HT-1376	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvkTWM2OD1{LkO4O\|A5KM7:TR?=	NEP5R4RUSU6JRWK=
LS-513	NX;2O2U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTOVmVKSzVyPUKuN\|g5PzRizszN	M3jOOHNCVkeHUh?=
KNS-42	NVX6XlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljqTWM2OD1{LkO5NVA2KM7:TR?=	Mk[xV2FPT0WU
639-V	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLPTHdKSzVyPUKuOFI4PThizszN	Mnf6V2FPT0WU
SJRH30	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYOwVYtIUUN3ME2yMlQ2OTZzIN88US=>	M{XsRnNCVkeHUh?=
SW1783	NH2z[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTCTWM2OD1{LkS3NFc5KM7:TR?=	MkPNV2FPT0WU
NB6	M{Du[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJwNEiyPEDPxE1?	NH3kSGZUSU6JRWK=
SK-MEL-30	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j1XmlEPTB;Mj60PFg{KM7:TR?=	M1zIT3NCVkeHUh?=
HCE-4	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYCyUXA5UUN3ME2yMlQ6PDB{IN88US=>	M3TIS3NCVkeHUh?=
NB10	NHznXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJwNEm0Nlkh\|ryP	M4nmS3NCVkeHUh?=
H-EMC-SS	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TOUWlEPTB;Mj61OFY2KM7:TR?=	NHnRUZpUSU6JRWK=
SK-HEP-1	NFrKe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[2UWlEPTB;Mj61OVI{PiEQvF2=	NGHZW3pUSU6JRWK=
HCC1395	NG\FR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG4[HZUUUN3ME2yMlU2PjV3IN88US=>	M3zTUnNCVkeHUh?=
HuCCT1	NFLtUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7sSIpTUUN3ME2yMlU3OzlizszN	M2fvdnNCVkeHUh?=
SiHa	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7xTWM2OD1{LkW4O\|E6KM7:TR?=	NVL3dmFYW0GQR1XS
EFO-21	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXETWM2OD1{LkW4O\|Y1KM7:TR?=	MW\TRW5ITVJ?
NCI-H1666	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4SwXmlEPTB;Mj61PVA4PiEQvF2=	NWToSYczW0GQR1XS
UMC-11	NGjLc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2npdWlEPTB;Mj61PVg3QCEQvF2=	M2C0UnNCVkeHUh?=
COLO-679	NHyzc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TYNGlEPTB;Mj62NVI{OyEQvF2=	NIH2fJlUSU6JRWK=
A388	M3XZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\RfJhKSzVyPUKuOlUzPTNizszN	MnP5V2FPT0WU
LB2518-MEL	NIPRXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvpVotKSzVyPUKuOlU1ODhizszN	MVTTRW5ITVJ?
EW-13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHvT5l[UUN3ME2yMlY5PzZ6IN88US=>	MV;TRW5ITVJ?
MLMA	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ToWWlEPTB;Mj62PFg2PiEQvF2=	MoPtV2FPT0WU
HOP-92	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nT[WlEPTB;Mj63NFEyKM7:TR?=	NEXEXFVUSU6JRWK=
NOMO-1	NHn0O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjDOlExUUN3ME2yMlcyPDR{IN88US=>	M1;OenNCVkeHUh?=
NCI-H810	M4e3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\ETWM2OD1{LkeyNVk5KM7:TR?=	NEXxbIxUSU6JRWK=
769-P	M33NeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\aTWM2OD1{LkeyNlgh\|ryP	MVvTRW5ITVJ?
SAS	M1TjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTJwN{[1JO69VQ>?	MYPTRW5ITVJ?
M059J	NVP0Z\|dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\mN4poUUN3ME2yMlc5OzF6IN88US=>	MoD1V2FPT0WU
RD	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TjPGlEPTB;Mj63PVQ4OSEQvF2=	NH\MOHlUSU6JRWK=
GT3TKB	M1ryZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJwOEO0N\|Mh\|ryP	M{XGb3NCVkeHUh?=
MZ7-mel	M{Da[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XxcWlEPTB;Mj64OlUxOiEQvF2=	M1fMNXNCVkeHUh?=
KYSE-510	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzuOnVKSzVyPUKuPFk2ODRizszN	MlTCV2FPT0WU
NCI-N87	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPjTYlKSzVyPUKuPVE5ODdizszN	NXnmZlBDW0GQR1XS
MKN1	NULwPYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L0XWlEPTB;Mz6wNFE3OyEQvF2=	M{fNfnNCVkeHUh?=
NCI-H2170	M4LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moe0TWM2OD1\|LkCwOFUyKM7:TR?=	M3e2Z3NCVkeHUh?=
OVCAR-3	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTNwMEKxNVUh\|ryP	MX\TRW5ITVJ?
KLE	NFnJV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjUToJKSzVyPUOuNFY5OTJizszN	NH\rRXJUSU6JRWK=
LB771-HNC	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PuVWlEPTB;Mz6wPVM1OyEQvF2=	NFrPXpdUSU6JRWK=
MC116	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;kTWM2OD1\|LkGxNVEzKM7:TR?=	MlX0V2FPT0WU
SCC-9	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrxT4lKSzVyPUOuNVE{PjZizszN	NF;IfphUSU6JRWK=
U031	NWrESZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTNwMUK0NlMh\|ryP	NGTjNYhUSU6JRWK=
LCLC-103H	M4PBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFOzZWFKSzVyPUOuNlM5QTRizszN	NIr3eFRUSU6JRWK=
U-266	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\rTWM2OD1\|LkK3OlM{KM7:TR?=	NUHPSJk3W0GQR1XS
JVM-2	NUTS[2lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13KZWlEPTB;Mz6zNlE3PCEQvF2=	Mny5V2FPT0WU
UACC-257	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTNwNE[0N\|Eh\|ryP	Mo\tV2FPT0WU
LB996-RCC	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoG3TWM2OD1\|LkS2OVAzKM7:TR?=	NUP0eWNkW0GQR1XS
BT-549	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LOVWlEPTB;Mz61NFIxQSEQvF2=	NF\1V2JUSU6JRWK=
NCI-H526	NHToUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr3cWJKSzVyPUOuOVQyPThizszN	NGP1VnhUSU6JRWK=
RH-18	M{nrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoT5TWM2OD1\|Lk[xO\|k5KM7:TR?=	MnS1V2FPT0WU
SW626	NH3u[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmC4TWM2OD1\|LkexNVI5KM7:TR?=	MX7TRW5ITVJ?
SK-N-AS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTNwN{OyOFch\|ryP	NWO0N3h1W0GQR1XS
IGR-1	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[2TWM2OD1\|Lke0NlQ5KM7:TR?=	MlzvV2FPT0WU
NCI-H2291	NWnsOpV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLNTWM2OD1\|Lke1N\|M3KM7:TR?=	NVfzTI9rW0GQR1XS
NCI-H441	M3TnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPL[olKSzVyPUOuPFI1OzNizszN	NIfrPY1USU6JRWK=
D-247MG	NV3zU5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHjVWNCUUN3ME2zMlg3ODNzIN88US=>	NYnxW\|RQW0GQR1XS
COLO-320-HSR	NXrRVY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrsTWM2OD1\|LkmxNlcyKM7:TR?=	NH3FbnBUSU6JRWK=
A253	NXjFV3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PHVWlEPTB;Mz65NVQ{PiEQvF2=	MmLMV2FPT0WU
HT55	M1n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTNwOUG3O\|Mh\|ryP	MkjpV2FPT0WU
MZ1-PC	NX\SZo5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLlZodMUUN3ME2zMlk2QDZ2IN88US=>	MYDTRW5ITVJ?
RERF-LC-MS	M3LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fDOGlEPTB;Mz65OlUzPSEQvF2=	MnfBV2FPT0WU
SF268	NVHqS2dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS3SoRsUUN3ME20MlEzQDhzIN88US=>	MYDTRW5ITVJ?
RMG-I	NY\MOGVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTRwMkG0OVQh\|ryP	MnraV2FPT0WU
CFPAC-1	NGOySXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zFVGlEPTB;ND6yNVY5PSEQvF2=	MVXTRW5ITVJ?
S-117	M{TZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1X5SGlEPTB;ND6yNlAzPCEQvF2=	NHHLeYVUSU6JRWK=
NCI-H2122	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTRwM{C5N\|Eh\|ryP	NEjUWY9USU6JRWK=
J82	NGC3W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1eyUWlEPTB;ND6zN\|Q1OSEQvF2=	NIGxeYRUSU6JRWK=
CAL-72	NHLUSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDxTIVKSzVyPUSuN\|U1PzdizszN	M4TjT3NCVkeHUh?=
GP5d	NWq1WW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTRwNEGyPVgh\|ryP	M1jyb3NCVkeHUh?=
UACC-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4G0SWlEPTB;ND60OlU1PSEQvF2=	NWTTZVNDW0GQR1XS
MS-1	NWTCb2tZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\NTWM2OD12LkS5NVE2KM7:TR?=	NYXiPIliW0GQR1XS
RCM-1	NWXuXVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq3TWM2OD12LkWyPVIh\|ryP	Ml[yV2FPT0WU
IST-SL1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTRwNkWzOVkh\|ryP	NYm3SmM1W0GQR1XS
SW756	M3W0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTRwNkmxN\|Uh\|ryP	MlLFV2FPT0WU
HCC38	NVvw[IVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTRwN{GxPVch\|ryP	NEHjbYpUSU6JRWK=
YAPC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXTcVRKSzVyPUSuO\|E{OTNizszN	NFqzdG5USU6JRWK=
DK-MG	NVO0SVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDaSIdKSzVyPUSuO\|gyOTJizszN	NHrhTI1USU6JRWK=
HCC1937	NUH5S4RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvsOpZiUUN3ME20Mlg2OTJ3IN88US=>	NWn2OYVqW0GQR1XS
OAW-28	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjVWIlKSzVyPUSuPVI1OzVizszN	NVTOOZdrW0GQR1XS
MEG-01	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPkTWM2OD13LkC4N\|I5KM7:TR?=	NYPoNoNCW0GQR1XS
GI-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fKSmlEPTB;NT6yN\|Q5PiEQvF2=	NFLPeXNUSU6JRWK=
FADU	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HCPWlEPTB;NT6yO\|g{PyEQvF2=	NXu5XpZvW0GQR1XS
CAPAN-1	NHLSV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTVwM{m0N\|Ih\|ryP	NGT3fHNUSU6JRWK=
TGBC11TKB	M{S2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTVwNEW3PFYh\|ryP	NXezN5dNW0GQR1XS
DBTRG-05MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\oTWM2OD13LkWwOVIh\|ryP	MkXmV2FPT0WU
ONS-76	NID0[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHJ[G9nUUN3ME21MlU2QDBzIN88US=>	NH;mTFJUSU6JRWK=
Ca-Ski	NVW1XFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLpTWM2OD13Lk[yOVY3KM7:TR?=	NVTtcZpYW0GQR1XS
COLO-741	NG\KSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXiPIhKSzVyPUWuO\|E6QTVizszN	NV;jdpJbW0GQR1XS
HT-29	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlj3TWM2OD13LkiwOFc2KM7:TR?=	NIKxNXVUSU6JRWK=
HCC1187	NXLJc2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTVwOEGwNFgh\|ryP	MlrQV2FPT0WU
Capan-2	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;2eWlEPTB;NT65OVk6PCEQvF2=	NYXL[25wW0GQR1XS
NCI-H630	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPsTWM2OD14LkGxOFQyKM7:TR?=	M3rJVHNCVkeHUh?=
COLO-678	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M122OmlEPTB;Nj6xOVA6OiEQvF2=	MWfTRW5ITVJ?
D-502MG	NEfqN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTZwMUezN\|Yh\|ryP	M3izO3NCVkeHUh?=
NB17	NVXldlJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDKRZZKSzVyPU[uNlQ6PDNizszN	NIqwRXdUSU6JRWK=
SK-MEL-24	NHnsNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PQO2lEPTB;Nj6yOlQ6KM7:TR?=	M1nmWHNCVkeHUh?=
NCI-SNU-5	NYLqVHZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTZwMkexNVgh\|ryP	Mnz2V2FPT0WU
D-392MG	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPkTWM2OD14LkOzN\|k6KM7:TR?=	NHTWZXBUSU6JRWK=
A498	NH\lT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXO0cFh4UUN3ME22MlQxOzB{IN88US=>	NYjLZohOW0GQR1XS
OCI-AML2	NIi4Z4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fqPWlEPTB;Nj60OVQ1PSEQvF2=	NXO0WXNUW0GQR1XS
HCC2157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTZwNEW2NVYh\|ryP	NIH0cXpUSU6JRWK=
C3A	NWPvVVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTZwNUKwNFQh\|ryP	NIqxS2FUSU6JRWK=
NCI-H1650	NXfHTZptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nKRWlEPTB;Nj63NFUzOiEQvF2=	MmnuV2FPT0WU
DU-145	M1jybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTZwN{ewN{DPxE1?	MWDTRW5ITVJ?
COLO-829	M3nyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHhTnRQUUN3ME22Mlc4QDd\|IN88US=>	M2nMVnNCVkeHUh?=
LS-1034	NGTEO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7NbpdKSzVyPUeuNFQ1OTJizszN	Mnn1V2FPT0WU
HCC1954	M2LKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTdwNEixN\|Qh\|ryP	NEHSbo1USU6JRWK=
KURAMOCHI	NUXCNmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnze2p1UUN3ME23MlQ5PTN\|IN88US=>	NXniZWtVW0GQR1XS
Mo-T	M1e0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHv4XotKSzVyPUeuOVE1QThizszN	M1H1dHNCVkeHUh?=
OE19	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDVNZVKSzVyPUeuOlU2ODNizszN	NIjofWFUSU6JRWK=
COR-L105	NILu[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjnUm1KSzVyPUeuO\|E1OjFizszN	MXfTRW5ITVJ?
NCI-H2342	NFvkXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vETWlEPTB;Nz63NVUzOSEQvF2=	M{m5XXNCVkeHUh?=
U-87-MG	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRThwMEOzN\|Qh\|ryP	NGL0NphUSU6JRWK=
MKN28	NGfGTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm2b\|NKSzVyPUiuNVE2OTVizszN	MWjTRW5ITVJ?
HT-1197	NXnWXpBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLpUG05UUN3ME24MlI2QTB5IN88US=>	NInLSnZUSU6JRWK=
ChaGo-K-1	NYCzZmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmexTWM2OD16LkO0NlQ2KM7:TR?=	NIrYVnJUSU6JRWK=
NCI-H226	NEnkXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDoWpRKSzVyPUiuOFQ{OzFizszN	NHjZZ4NUSU6JRWK=
NCI-H2029	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTlwME[3OVkh\|ryP	MXPTRW5ITVJ?
TE-11	NVrM[m5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTlwNEW1PFgh\|ryP	Mk\vV2FPT0WU
ZR-75-30	NFjUUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fkU2lEPTB;OT65NlY{PCEQvF2=	NX3N[3ZtW0GQR1XS
SW837	M{DyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M365S2lEPTB;MUCuNlI6OyEQvF2=	Mm\kV2FPT0WU
NCI-H1651	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFyLkKzNlYh\|ryP	MUDTRW5ITVJ?
NCI-H727	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFyLkS0PVUh\|ryP	NXLvSmplW0GQR1XS
NCI-H358	M3\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHWTWM2OD1zMD64N\|Y2KM7:TR?=	NVzwW3NnW0GQR1XS
NCI-H2087	NGe0bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq0[YxKSzVyPUGxMlA1OzRizszN	NUD4cm9YW0GQR1XS
FTC-133	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXPUHRDUUN3ME2xNU41ODVzIN88US=>	M1jVcXNCVkeHUh?=
LAN-6	NICzT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTyeZVKSzVyPUGyMlEzPCEQvF2=	MYnTRW5ITVJ?
NCI-H1838	NXvKTnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF{LkWxOVEh\|ryP	NXywUWtwW0GQR1XS
Calu-6	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfJNYJHUUN3ME2xOE4yODJzIN88US=>	NIP2elNUSU6JRWK=
HCC70	NX;ZcIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTwTWM2OD1zND60OVEh\|ryP	MWfTRW5ITVJ?
KARPAS-299	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF3LkKxOVkh\|ryP	M{DXTXNCVkeHUh?=
CAL-27	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmi1TWM2OD1zNT6zPFQ{KM7:TR?=	Moe1V2FPT0WU
NCI-H82	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3vTWM2OD1zNT61N\|Ih\|ryP	NX;RNId4W0GQR1XS
no-10	NH3sTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjFTWM2OD1zNT65N\|gh\|ryP	MmLRV2FPT0WU
U251	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF4LkO2O\|Uh\|ryP	M2fIenNCVkeHUh?=
TE-9	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm4T2FlUUN3ME2xO{42OTZ4IN88US=>	NHvpZYtUSU6JRWK=
TE-10	NYHQdJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f2fGlEPTB;MUmuNFYxPyEQvF2=	NXXxNWZNW0GQR1XS
COLO-824	NFL2PGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[wUotKSzVyPUKwMlkzPzZizszN	NYn2OW9bW0GQR1XS
HuP-T3	M13lXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHsToVKSzVyPUKxMlA4PDhizszN	NWWwWZB6W0GQR1XS
KALS-1	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD1PHpvUUN3ME2yNU4yPzVizszN	Mnv5V2FPT0WU
L-428	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\LT2lEPTB;MkGuOFAyPiEQvF2=	M1rPXnNCVkeHUh?=
JAR	NIjP[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC1Sm5VUUN3ME2yNU42ODJizszN	M{\zR3NCVkeHUh?=
DoTc2-4510	M2LZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULNcVJtUUN3ME2yN{45PDd3IN88US=>	NUK5OWtMW0GQR1XS
ABC-1	NFTJ[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTJ4Lke5OVch\|ryP	M3PZTnNCVkeHUh?=
MHH-NB-11	M4HqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTN\|LkO0OlQh\|ryP	NG\jPJJUSU6JRWK=
SW1463	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\iRllKSzVyPUOzMlk5OyEQvF2=	MnPmV2FPT0WU
SW1417	NYrDO3Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTN5LkC5OVIh\|ryP	NFSyPHFUSU6JRWK=
NB12	M2K1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO3R4dyUUN3ME2zPU41PjV3IN88US=>	MoDCV2FPT0WU
NY	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXDZpgzUUN3ME20NU4{OjBzIN88US=>	M{XFfXNCVkeHUh?=
H1048	MoDwRZBweHSxc3nzJGF{e2G7	M170S\|UxOCCwTR?=	Mm\qO\|IhcA>?		NEPYS3hvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MkPjNlU4Ozd3NEK=
H86	MkL4RZBweHSxc3nzJGF{e2G7	MV21NFAhdk1?	M2POblczKGh?		NEHqWYtvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MmLZNlU4Ozd3NEK=
H196	M1P6[mFxd3C2b4Ppd{BCe3OjeR?=	MY[1NFAhdk1?	NFPuSIs4OiCq		MlL1cohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	NGKwS\|UzPTd\|N{W0Ni=>
H446	MV\BdI9xfG:\|aYOgRZN{[Xl?	MVq1NFAhdk1?	M1rOSVczKGh?		NV7YUZRudmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NFviPIszPTd\|N{W0Ni=>
TFK-1	M2P5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWXMSnJDPzJiaB?=	NWjXXVlSTE2VTx?=	MkLKTWM2OD12NzDuUS=>	MorJNlUyPTJ{NES=
EGI-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1qyWlczKGh?	NW\sPFVOTE2VTx?=	NV3KZWtYUUN3ME21N{BvVQ>?	MknlNlUyPTJ{NES=
OCI/AML3	M4KwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:wMlIh\|ryP	MoH3OFghcA>?		MXjlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	M2fKdFI1PzN7M{mz
U937	M1nrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;CZlMxOC5{IN88US=>	NEDvOXg1QCCq		M3\3[oVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDz[Yx2dWW2aX7pZi=>	M4fES\|I1PzN7M{mz
MOLM13	M3vEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG3NE4zKM7:TR?=	NF3UO4M1QCCq		NIXQdohmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	MkXSNlQ4Ozl\|OUO=
MCF7	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fYXFIxKG6P	NFryVHk4OiCq	NVmyOmc5TkKV	M1XJR5Jm\HWlZYOgeIhmKFCHTGCxMY1m\GmjdHXkJIlv[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5	MVeyOFY5QDB2Nh?=
TamR	M3qyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3K3[mlEPTB;MUlihKlvVQ>?	MnLmNlQ1PTdyNkm=
MCF7-X	M{HRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXqwS3VEUUN3ME2yOEBvVQ>?	NFXJfIUzPDR3N{C2PS=>
T47D-tamR	NEPZOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF7IH7N	M1POc\|I1PDV5ME[5
293T	NX\NWXJFTnWwY4Tpc44hSXO\|YYm=	NXXJZ4FmOjBibl2=	NYj0W2tjOyCq		NEO0NGNlcXO{dYD0d{BCc3RvbXXkbYF1\WRiVFnGMWlCKHO2YXLpcIl1gSxidILhcpNtd2OjdHnvckwh[W6mIHHjeIl3cXS7	M{TDXFI1OzZ\|NES5
SW620	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XXcFAvODBzLUGw{txO	NXjDc5VpOjRiaB?=		M3TQUYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYOgeIhmKGOxbnPlcpRz[XSrb36gdol{\XN?	NYmyNG97OjR\|NkO0OFk>
Huh7	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYW1MVExOCCwTR?=	NX\sSoFROC1{NDDo	MmnTSG1UVw>?	MXPpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	Ml3VNlQzQTd\|MEC=
Hep3B	NE\CS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfuOGY2NTFyMDDuUS=>	MW[wMVI1KGh?	NUTIPZNETE2VTx?=	NVXWPFlHcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	MlnINlQzQTd\|MEC=
Huh7	MkDMSpVv[3Srb36gRZN{[Xl?	M{fKclExOCCwTR?=	MmCzNVIhcA>?	NG\nOmhFVVOR	MWPpcoR2[2W\|IHH1eI9xcGGpedMg	NFvvc3gzPDJ7N{OwNC=>
U87-MG	NEX2SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYe3NkBp		M1\zUWdKPTEkgJm95qCKPzlibl5CpC=>	MkXmNlQzPDl4NEC=
L3.6pl	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e3SFEh\|ryP	NVf4blR1PzJiaB?=		MWfpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBDVVNvN{e3OlA4	NYiyc5VyOjR{M{OzPVk>
TE671	NGHIfplCeG:ydH;zbZMhSXO\|YYm=	NEG1W4MyKM7:TR?=	MmXnOFghcA>?		NGTJU\|FqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	NUXpXIRzOjRzM{OyNVg>
RD	M3jBc2Fxd3C2b4Ppd{BCe3OjeR?=	Mn7ENUDPxE1?	M1fHOVQ5KGh?		MlzlbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	M4TlflI1OTN\|MkG4
RMS13	M1fCe2Fxd3C2b4Ppd{BCe3OjeR?=	MYCxJO69VQ>?	MVq0PEBp		NVHpeIR3cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	NFS0WVIzPDF\|M{KxPC=>
RH30	MofFRZBweHSxc3nzJGF{e2G7	NWXwOlR1OSEQvF2=	M{Hu[FQ5KGh?		NFO4RZZqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	NH[5Sm0zPDF\|M{KxPC=>
Hep-2	M4HLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCwMlAyNTFizszN	M{i2PFEzNTl4IHi=		M3XhTIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MmW3NlQyODN5NEm=
SCC-9	M1viRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjLNE4xOS1zIN88US=>	MonHNVIuQTZiaB?=		M1rhZ4lv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	M13HdlI1OTB\|N{S5
Hep-2	NGK1U4RHfW6ldHnvckBCe3OjeR?=	M{K5eVAvOS9yLkWg{txO	M1HWd\|I1KGh?		M1jJbYJtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	MUKyOFExOzd2OR?=
SCC-9	MXPGeY5kfGmxbjDBd5NigQ>?	M1nGUVAvOS9yLkWg{txO	NHPYbJczPCCq		MorjZoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	NYK2UlNnOjRzMEO3OFk>
PANC-1	MkHxRZBweHSxc3nzJGF{e2G7	Mk\xOVAxKG6P	MVu0PEBp		MmH2d4Vve2m2aYrld{Bx[W6lcnXheIlkKGOjbnPldkBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	NIDwTZgzOzh6NkK5OC=>
RMG2	MmfPRZBweHSxc3nzJGF{e2G7	M3;aSFEuOTByMDDuUS=>	NWnnZpFuPzJiaB?=	Mo[ySmJU	MkDGbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	Mn7hNlM3OTV4M{G=
HAC2	NUnoOJM4SXCxcITvd4l{KEG\|c3H5	MYGxMVExODBibl2=	MXi3NkBp	NHTXcW9HSlN?	M1P1[olvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MUmyN\|YyPTZ\|MR?=
HT-29	MmnWRZBweHSxc3nzJGF{e2G7	NWT1V2luOSEQvF2=	M4fzXVczKGh?		M3zMO4F1fGWwdXH0[ZMhPS2IVT3pcoR2[2WmIHPlcIwh\GWjdHi=	NV\tXIY3OjF7NEmxNlE>
DLD1	MUTBdI9xfG:\|aYOgRZN{[Xl?	MmLJNUDPxE1?	MX23NkBp		NUPWXYZ2[XS2ZX71ZZRmeyB3LV\VMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MY[yNVk1QTF{MR?=
HT-29	NWrKbVJlTnWwY4Tpc44hSXO\|YYm=	MYqxJO69VQ>?	MVK3NkBp		MXzpcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	MXyyNVk1QTF{MR?=
DLD1	NXX3W4FRTnWwY4Tpc44hSXO\|YYm=	MWKxJO69VQ>?	MlX4O\|IhcA>?		MVXpcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	NWDqdWJ7OjF7NEmxNlE>
Rh41	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXEfoszUUN3ME2zNE44KG6P	MlfMNlE{Ozd4N{m=
Rh18	NVLyUGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn23TWM2OD12MT60JI5O	NXvBVoJ[OjF\|M{e2O\|k>
Rh30	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLsWJBKSzVyPUG0JI5O	MY[yNVM{PzZ5OR?=
BT-12	NHf1UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXqTWM2OD1{ND63JI5O	MXWyNVM{PzZ5OR?=
CHLA-266	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLreZpKSzVyPUGuNUBvVQ>?	Mnq2NlE{Ozd4N{m=
TC-71	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTR4LkWgcm0>	MUKyNVM{PzZ5OR?=
CHLA-9	NFz0RoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHSTWM2OD1zNT6zJI5O	NYj2d2NIOjF\|M{e2O\|k>
CHLA-10	NFG0TZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\MbnJKSzVyPUOuPUBvVQ>?	NInvRVEzOTN\|N{[3PS=>
CHLA-258	NYjzSI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFyLkSgcm0>	M2TTZlIyOzN5Nke5
GBM2	NGjHXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUS3NYF{UUN3ME20NE44KG6P	MVSyNVM{PzZ5OR?=
NB-1643	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTN\|Lkigcm0>	NGPqToszOTN\|N{[3PS=>
NB-EBc1	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHBWmNKSzVyPUK3MlEhdk1?	NXrVd5BkOjF\|M{e2O\|k>
CHLA-90	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTN2LkWgcm0>	M{PKVFIyOzN5Nke5
CHLA-136	M{K0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\yeoVKSzVyPUG2Nk43KG6P	NEXxNG4zOTN\|N{[3PS=>
NALM-6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTN{Lkmgcm0>	MUKyNVM{PzZ5OR?=
COG-LL-317	MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwMzDuUS=>	NUW3NFdHOjF\|M{e2O\|k>
RS4;11	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K5RmlEPTB;M{Wgcm0>	M{jGTVIyOzN5Nke5
MOLT-4	NVvnTW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\1TWM2OD16Lk[gcm0>	NF65[JQzOTN\|N{[3PS=>
CCRF-CEM	NYP4b\|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITnNpNKSzVyPUSuNUBvVQ>?	NIGzRXIzOTN\|N{[3PS=>
Kasumi-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLhTWM2OD1zLkSgcm0>	M2S5bVIyOzN5Nke5
Karpas-299	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH2TWM2OD1{MT63JI5O	M{HCZ\|IyOzN5Nke5
Ramos-RA1	NU\JN2J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRThwMjDuUS=>	NX7K[XZkOjF\|M{e2O\|k>
H838	NUHrbXhGTnWwY4Tpc44hSXO\|YYm=	MlexNUDPxE1?	NHy5clQ1QCCq		NWHROHl2cW6mdXPld{Bk\WyuIHH1eI9xcGGpeR?=	NVK0SoxCOjB\|NkSxNVM>
H838	NWjsc3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2X3TVAuOyEQvF2=	MVm3NkBp		MnXIbY5lfWOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh[XW2b4DoZYd6	MmLuNlAxOjh6NUS=
A549	NXHXUopWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz2V3MxNTNizszN	NGjYfFg4OiCq		MXTpcoR2[2W\|IHfyc5d1cCCrbnjpZol1cW:wIHHu[EBifXSxcHjh[5k>	MYCyNFAzQDh3NB?=

... Click to View More Cell Line Experimental Data

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	+ Expand Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	+ Expand Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

+ Expand

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1
NCT00731263	Completed	Solid Tumors	AstraZeneca	July 2008	Phase 1
NCT01194193	Withdrawn	Cancer\|Advanced Solid Tumours\|Lymphomas	AstraZeneca	null	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 38 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 38 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)